Can-Fite BioPharma Ltd. - PE Ratio
CANF.TA
Price:
$529.7
Market Cap:
$7.56M
Can-Fite BioPharma Ltd. is an Israel-based, clinical-stage biopharmaceutical firm dedicated to developing small molecule therapeutic agents. Its research and development efforts are concentrated on addressing conditions such as cancer, various liver inflammatory diseases, and erectile dysfunction. The company's lead investigational compound, Piclidenoson, has progressed through successful completion of its Phase III clinical trial for psoriasis and a Phase II clinical trial for COVID-19. Another promising candidate, Namodenoson, is presently undergoing a Phase III trial for hepatocellular carcinoma and a Phase IIb trial for non-alcoholic steatohepatitis. Furthermore, CF602 is in its pre-clin...[Read more]
Industry
Biotechnology
IPO Date
2005-10-06
Stock Exchange
TLV
Ticker
CANF.TA
PE Ratio
[-0.56]
ROE
[-201.06%]
Current Ratio
[3.46]
Dividend Yield
[0%]
Enterprise Value
[2.11M]
Dividend History
The PE Ratio as of August 2026 (TTM) for Can-Fite BioPharma Ltd. (CANF.TA) is -0.56
According to Can-Fite BioPharma Ltd.’s latest financial reports and current stock price. The company's current PE Ratio is -0.56. This represents a change of -99.98% compared to the average of -2396.35 of the last 4 quarters.
Can-Fite BioPharma Ltd. (CANF.TA) Historical PE Ratio (quarterly & annually)
How has CANF.TA PE Ratio performed in the past?
The mean historical PE Ratio of Can-Fite BioPharma Ltd. over the last ten years is -5907.57. The current -0.56 PE Ratio has changed -99.05% with respect to the historical average. Over the past ten years (40 quarters), CANF.TA's PE Ratio was at its highest in in the September 2025 quarter at -1.97. The PE Ratio was at its lowest in in the September 2018 quarter at -111467.02.
Average
-5907.57
Median
-4560.16
Minimum
-12107.32
Maximum
-1.46
Can-Fite BioPharma Ltd. (CANF.TA) PE Ratio by Quarter and Year
Discovering the peaks and valleys of Can-Fite BioPharma Ltd. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 103.03%
Maximum Annual PE Ratio = -1.46
Minimum Annual Increase = -99.97%
Minimum Annual PE Ratio = -12107.32
| Year | PE Ratio | Change |
|---|---|---|
| 2025 | -1.46 | -99.97% |
| 2024 | -4345.46 | 16.99% |
| 2023 | -3714.25 | -26.40% |
| 2022 | -5046.86 | 6.68% |
| 2021 | -4730.75 | 7.77% |
| 2020 | -4389.57 | 103.03% |
| 2019 | -2162.02 | -80.24% |
| 2018 | -10941.33 | -5.98% |
| 2017 | -11636.69 | -3.89% |
| 2016 | -12107.32 | -26.14% |
Can-Fite BioPharma Ltd. (CANF.TA) Average PE Ratio
How has CANF.TA PE Ratio performed in the past?
The current PE Ratio of Can-Fite BioPharma Ltd. (CANF.TA) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-2687.06
5-year avg
-3567.76
10-year avg
-5907.57
Can-Fite BioPharma Ltd. (CANF.TA) PE Ratio vs. Peers
How is CANF.TA’s PE Ratio compared to its peers?
Can-Fite BioPharma Ltd.’s PE Ratio is greater than BioLineRx Ltd. (-1.39), greater than Clal Biotechnology Industries Ltd. (-2.78), less than Evogene Ltd. (-0.48), greater than XTL Biopharmaceuticals Ltd. (-0.87), greater than Matricelf Ltd. (-1.33), greater than BioLight Life Sciences Ltd. (-1.79), less than Together Pharma Ltd. (19.57), less than Purple Biotech Ltd. (-0.01), greater than Identi Healthcare Ltd. (-4.59), less than Enlivex Therapeutics Ltd. (0.01),
| Company | PE Ratio | Market cap |
|---|---|---|
| -1.39 | $39.16M | |
| -2.78 | $38.43M | |
| -0.48 | $17.44M | |
| -0.87 | $19.87M | |
| -1.33 | $44.25M | |
| -1.79 | $18.59M | |
| 19.57 | $41.55M | |
| -0.01 | $5.38M | |
| -4.59 | $27.79M | |
| 0.01 | $65.55M |
Build a custom stock screener for Can-Fite BioPharma Ltd. (CANF.TA) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Can-Fite BioPharma Ltd. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Can-Fite BioPharma Ltd. (CANF.TA) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Can-Fite BioPharma Ltd. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the PE Ratio?
How can you use the PE Ratio?
What is Can-Fite BioPharma Ltd.'s PE Ratio?
How is the PE Ratio calculated for Can-Fite BioPharma Ltd. (CANF.TA)?
What is the highest PE Ratio for Can-Fite BioPharma Ltd. (CANF.TA)?
What is the 3-year average PE Ratio for Can-Fite BioPharma Ltd. (CANF.TA)?
What is the 5-year average PE Ratio for Can-Fite BioPharma Ltd. (CANF.TA)?
How does the current PE Ratio for Can-Fite BioPharma Ltd. (CANF.TA) compare to its historical average?